Screening for pulmonary arterial hypertension in patients with scleroderma—A New Zealand perspective

New Zealand Medical Journal

Volumn 127, Issue 1400, 2014, Pages 30-38

  Ghosh, Sanjib K ^a   Corkill, Michael M ^b   Hart, Hamish H ^b   Ng, Kristine P ^b  

^a Northland District Health Board   (New Zealand)

^b NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; PERIPHERAL VASODILATING AGENT; PROSTACYCLIN DERIVATIVE; SILDENAFIL; ANTIHYPERTENSIVE AGENT; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; SULFONE; VASODILATOR AGENT;

6 MINUTE WALK TEST; ARTICLE; CLINICAL EXAMINATION; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC TEST; DIFFUSE SCLERODERMA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART CATHETER; HUMAN; INTERSTITIAL LUNG DISEASE; LIMITED SCLERODERMA; LUNG FUNCTION TEST; NEW ZEALAND; PULMONARY HYPERTENSION; QUESTIONNAIRE; RHEUMATOLOGY; SCLERODERMA; SCREENING; CLINICAL PRACTICE; EXERCISE TEST; HEART CATHETERIZATION; MASS SCREENING; METHODOLOGY; PHYSICAL EXAMINATION; STATISTICS; SYSTEMIC SCLEROSIS;

ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; HUMANS; HYPERTENSION, PULMONARY; MASS SCREENING; NEW ZEALAND; PHYSICAL EXAMINATION; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PURINES; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SULFONES; VASODILATOR AGENTS;

EID: 84907524349     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998; 17: 48-54.
2. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J. 2009 Oct; 39(10): 682-91.
3. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010; 37: 2290-8.
4. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005; 52: 2125-32.
5. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37: 1283-9.
6. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118: 2-10.
7. Launay D, Humbert M, Hachulla E. Pulmonary arterial hypertension and systemic sclerosis. Presse Med. 2006; 35: 1929-37.
8. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009; 60: 569-77.
9. Mangat P, Conron M, Gabbay E, Proudman SM. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians. Intern Med J. 2010; 40: 494-502.
10. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52: 3792-800.
11. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev. 2010; 19: 314-20.
12. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007; 37: 485-94.
13. Vachiéry JL, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev. 2009; 18: 162-9.
14. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 30: S55-66.
15. Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken). 2012; 64: 303-10.
16. Hachulla E, Coghlan JG. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis. 2004; 63: 1009-14.
17. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009; 48: 32-5.
18. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006; 54: 184-91.
19. Ng K, Gow P. Management of scleroderma in a New Zealand tertiary rheumatology centre: emphasis on pulmonary complications. N Z Med J. 2007; 120(1254): U2537.
20. Galie N, Hoeper M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
21. McLaughlin V, Archer SL, Badesh DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc and the Pulmonary Hypertension Association, Circulation. 2009; 119: 2250-94.
22. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long term survival. Arthritis Rheum. 2011; 63: 3522-30.
23. Coghlan J, Denton C, Grunig E, et al. Evidence-based detection of pulmonary hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2013 May 18 (Epub ahead of print).
24. Wilson JMG, Jungner G. Principles and Practice of screening for disease, World Health Organisation, 1968.
25. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis. 2007; 66: 169-73.
26. Wilsher M, Good N, Hopkins R, et al. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology. 2012; 17: 647-52.
27. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis. 2009; 68: 620-8.
28. Chung L, Chen H, Khanna D, et al. Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: Utility of the University of California, San Diego Shortness of Breath Questionnaire. Arthritis Care Res. 2013; 65(3): 454-63.